Menu

Oprah to Star in Henrietta Lacks Movie

She will also be an executive producer on the HBO Films project, which is based on a 2010 book about the life of Henrietta Lacks.

May 3, 2016
Tanya Lewis

HeLa cellsWIKIMEDIA, NIHOprah Winfrey will star in an upcoming HBO Films movie based on Rebecca Skloot’s book “The Immortal Life of Henrietta Lacks,” Variety reported yesterday (May 2). In addition to producing the film, Winfrey will play the role of Deborah Lacks, daughter of Henrietta Lacks, whose cells were harvested and used without her permission and have played an essential role in medical research.

“Thrilled about this for many reasons. Top on list:Deborah Lacks dreamed @Oprah would someday play her in #HeLa movie,” Skloot tweeted yesterday.

Henrietta Lacks died in 1951, but her cancerous cells, dubbed HeLa cells, formed the basis of an immortal cell line that helped lay the foundation for a polio vaccine, as well as for some cancer and HIV research, according to The Verge. The book and film tell the story of Lacks and her family, whose contributions went unrecognized for decades.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.